Share on StockTwits

Equities Research Analysts’ ratings reiterations for Monday, August 18th:

Biogen Idec (NASDAQ:BIIB) had its overweight rating reissued by analysts at Morgan Stanley. The firm currently has a $395.00 price target on the stock. The analysts wrote, “Friday’s approval was in-line with expectations following a 3 month PDUFA date extension. The label appears consistent with Avonex. Both drugs demonstrated similar annualized relapse rates (ARR) vs placebo, ~30-34% for Avonex and 36% for Plegridy, but Plegridy is dosed every two weeks while Avonex is dosed weekly. The monthly dose of Plegridy achieved a lower ARR (~28%) and is not labeled, though it may be used off-label for certain patients.”

Cardinal Health (NYSE:CAH) had its buy rating reissued by analysts at Argus. The firm currently has a $71.43 target price on the stock, down from their previous target price of $83.00.

CareFusion (NYSE:CFN) had its buy rating reaffirmed by analysts at Bank of America. Bank of America currently has a $43.97 price target on the stock, down from their previous price target of $50.00.

JD.Com Inc(ADR) (NYSE:JD) had its market perform rating reiterated by analysts at Cowen and Company.

The Coca-Cola Company (NYSE:KO) had its outperform rating reissued by analysts at Credit Suisse. They currently have a $46.00 price target on the stock.

Lions Gate Entertainment Corp. (NYSE:LGF) had its buy rating reaffirmed by analysts at Argus. The firm currently has a $41.00 price target on the stock.

Londonmetric Property PLC (LON:LMP) had its hold rating reiterated by analysts at Liberum Capital. Liberum Capital currently has a GBX 142 ($2.37) price target on the stock.

Medivation (NASDAQ:MDVN) had its positive rating reissued by analysts at Jefferies Group.

Newmont Mining Corp (NYSE:NEM) had its buy rating reiterated by analysts at Sterne Agee. Sterne Agee currently has a $26.89 target price on the stock, down from their previous target price of $30.00.

Union Pacific (NYSE:UNP) had its outperform rating reiterated by analysts at Credit Suisse. Credit Suisse currently has a $119.00 price target on the stock, up from their previous price target of $115.00. The analysts wrote, “We have raised our FY14 EPS forecast to $5.59 from $5.56. We have also raised our FY15 and FY16 EPS estimates to $6.54 and $7.46 from $6.48 and $7.38, respectively. Our TP rises to $119 from $115, primarily due to a higher base year EBIT. Reiterate Outperform.”

Wheeler Reit (NASDAQ:WHLR) had its buy rating reiterated by analysts at Maxim Group.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.